Clinical Trial Update: Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating anlotinib plus TQB2450 with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• TQB2450

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Advanced Biliary Tract Cancer | Phase 2 | Status: UNKNOWN